These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 26075448

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM.
    Cancer Lett; 2013 Jul 10; 335(1):1-8. PubMed ID: 23419523
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeted therapy for renal cell cancer: current perspectives.
    van der Veldt AA, Haanen JB, van den Eertwegh AJ, Boven E.
    Discov Med; 2010 Nov 10; 10(54):394-405. PubMed ID: 21122471
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M, Si S, Li Y, Schoen S, Xiao GQ, Li X, Teh BT, Wu G, Chen J.
    Oncotarget; 2015 Oct 20; 6(32):32761-73. PubMed ID: 26418749
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S.
    Expert Opin Investig Drugs; 2017 Nov 20; 26(11):1229-1237. PubMed ID: 28952411
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH, Molina AM, Motzer RJ.
    Hematol Oncol Clin North Am; 2011 Aug 20; 25(4):835-52. PubMed ID: 21763970
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.